[Hydrocortisone 17-butyrate (Locoid), a thirty-year ongoing innovative drug].
G E Piérard
Index: Rev. Med. Liege. 61(2) , 128-30, (2006)
Full Text: HTML
Abstract
Since half a century, dermocorticoids represent worthy compounds in dermatological therapy. About thirty years ago, hydrocortisone 17-butyrate was introduced on the Belgian market. This compound combines good efficiency and reduced risk of side effects. Its topical formulations have been enriched over time. The original Locoid lipocream and Locoid Crelo presentations confer remarkable qualities to the product. We report a synopsis of clinical and translational studies devoted to this unique dermocorticoid.
Related Compounds
Related Articles:
Functional consequence of the MET-T1010I polymorphism in breast cancer.
2015-02-20
[Oncotarget 6(5) , 2604-14, (2015)]
Cell-cell adhesions and cell contractility are upregulated upon desmosome disruption.
2014-01-01
[PLoS ONE 9(7) , e101824, (2014)]
MYC is a critical target of FBXW7.
2015-02-20
[Oncotarget 6(5) , 3292-305, (2015)]
2015-01-01
[PLoS ONE 10(2) , e0118336, (2015)]
Myricetin and naringenin inhibit human squamous cell carcinoma proliferation and migration in vitro.
2014-01-01
[Nutr. Cancer 66(7) , 1257-67, (2014)]